mGluR2 Modulators via Substituted Dihydropyrazinone Derivatives
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders such as depression and cognitive dysfunction, particularly those targeting the metabotropic glutamate receptor subtype 2 (mGluR2), face limitations in efficacy and specificity, with existing compounds often having side effects and limited therapeutic benefits.
Innovation Solution
Development of 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the mGluR2 receptor, which are designed to enhance glutamatergic signaling by acting as therapeutically effective compounds for mood disorders, cognitive impairments, and other central nervous system conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing mGluR2 antagonists and negative allosteric modulators are used to treat neurological disorders, then therapeutic benefits are achieved, but side effects and limited efficacy occur
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of mGluR2 modulators through various substituents (R1-R6 groups) to optimize the balance between therapeutic efficacy and side effect profile. Different substituent patterns allow fine-tuning of receptor binding characteristics and pharmacokinetic properties to improve reliability while reducing harmful effects
Solution Approach 2:
The invention employs composite molecular structures combining pyrazolo[1,5-a]pyrazin-4(5H)-one core with diverse substituent groups (aryl, heteroaryl, alkyl, halo groups) to create compounds with optimized pharmacological properties. This composite approach allows integration of multiple functional characteristics into single molecules that achieve both efficacy and reduced side effects
2Productivity
If current mGluR2 targeting compounds are used, then treatment of mood disorders and cognitive dysfunction is attempted, but limited therapeutic benefits are achieved
Solution Approach 1:
The patent utilizes parameter changes by varying key molecular parameters including substituent types, positions, and configurations to enhance therapeutic benefit. The systematic exploration of different R group combinations enables optimization of both potency and selectivity, thereby improving efficacy for treating mood disorders and cognitive dysfunction
Solution Approach 2:
The invention achieves universality by designing mGluR2 modulators with broad therapeutic applicability across multiple neurological conditions including depression, anxiety, and cognitive disorders. The core molecular structure maintains multi-functional capability to address diverse pathological mechanisms while targeting the same receptor subtype
Data Source
AI summary
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.